Form D — Imbria Pharmaceuticals, Inc.
0001745672-25-000003 · filed Apr 1, 2025
Offering amounts describe securities offered; amounts sold are issuer-reported as of each filing. Amendments can repeat earlier amounts. We do not add these figures into a capital-raised total. Missing amounts are not zero. Data coverage and methodology · How to interpret the amounts.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Reported offering amount
- $124,195,815
- Reported amount sold
- $59,195,818
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Imbria Pharmaceuticals, Inc.
- CIK
- 1745672
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- —
- Address
- 265 FRANKLIN STREET
BOSTON, MA 02110 - Phone
- 917-657-5069
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Alvin Shih · DirectorBoston, MA Find on LinkedIn ↗
-
Andrew Levin · DirectorBoston, MA Find on LinkedIn ↗
-
James Januzzi · DirectorBoston, MA Find on LinkedIn ↗
-
Charles Dunn · DirectorBoston, MA Find on LinkedIn ↗
-
Komal Joshi · Executive OfficerBoston, MA Find on LinkedIn ↗
-
Rebecca Luse · DirectorBoston, MA Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗